Effects of indeloxazine, (+)-2-[inden-7-yloxy)methyl]morpholine hydrochloride on cerebrospinal fluid monoamine metabolites.
Effects of indeloxazine, a new compound which has been though to block reuptake of serotonin and noradrenaline, on cerebrospinal fluid monoamine metabolites were evaluated in 11 patients with dementia. Treatment with 90 mg/day of indeloxazine for 6-8 weeks resulted in significant reduction in methoxyhydroxyphenylen glycol and 5-hydroxyindoleacetic acid in these patients. These findings are consistent with results reported in experimental animals. The mode of action with respect to changes in monoamine metabolites and therapeutic implications of this compound are discussed.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D004298:Dopamine / Q000134:cerebrospinal fluid; D005260:Female; D006018:Glycols / Q000134:cerebrospinal fluid*; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid*; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology* / Q000627:therapeutic use
D006018:Glycols; D009025:Morpholines; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; C020852:indeloxazine; D004298:Dopamine; D006719:Homovanillic Acid